CL

Business profile & competitive position

Colgate-Palmolive Company is a Consumer Defensive business in the Household & Personal Products industry. It operates through two primary segments: Oral, Personal and Home Care (toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners) and Hill’s Pet Nutrition (specialty dog and cat foods). The company markets its products in over 200 countries and territories through retailers, wholesalers, eCommerce retailers, veterinarians and certain direct-to-consumer channels.

The 2025 sales mix underscores where revenue actually comes from: Oral Care 44%, Personal Care 17%, Home Care 16% and Pet Nutrition 23%. Walmart and its affiliates represented approximately 11% of 2025 net sales, and no other customer exceeded 10%. That level of customer concentration is a meaningful structural detail for a consumer staples name, even though the overall end-demand profile is diversified by geography and category.

On profitability, the numbers are striking in different directions. Net margin is 9.7%, which is respectable but not extraordinary for a premium-branded staples company. Return on equity, however, is 631.1%—a figure that signals an extremely equity-light capital structure (historically driven by sizeable share buybacks and accumulated liabilities) rather than a simple “high-margin” moat. Taken together with a beta of 0.32, the picture is of a low-volatility, globally distributed brand owner whose competitive strength lies in distribution reach and repeat-purchase categories, supported by operational leverage more than by outsized raw margins.

Financial posture

Colgate-Palmolive’s current market capitalization is $69.3 billion, and it trades at a trailing P/E of 34.1. That multiple sits well above what raw profitability alone might suggest: a 9.7% net margin and even the eye-catching 631.1% ROE do not, by themselves, justify a 34x earnings valuation. The premium is better understood as pricing in the company’s defensive cash-flow profile, its consistent earnings history and its low beta of 0.32.

At the current snapshot, the stock is $86.65, below its 50-day EMA of $89.81, with an RSI of 37.0. That places the price just off technical support territory and below its short-term moving average, suggesting near-term momentum has weakened even as the underlying business remains a large-cap staple.

Strategic priorities & outlook

Colgate-Palmolive’s most recent 10-K filing outlines a clear set of operational priorities:

• Drive organic sales growth and deliver consistent, compounded earnings-per-share growth.
• Achieve operational efficiencies while growing free cash flow and using the balance sheet efficiently.
• Leverage global brand reach, science-based innovation, an agile supply chain and best-in-class omni-channel demand generation.
• Build capabilities in data, analytics and artificial intelligence and evolve a high-impact, inclusive culture.

The filing also flags important operational realities. As of December 31, 2025, the company had approximately 33,600 employees across more than 100 countries, with over 84% located outside the United States. The sales mix (Oral Care 44%, Pet Nutrition 23%) and the Walmart concentration (~11% of net sales) are consistent themes that tie financial results to global consumer behavior, pet-category trends and a small number of large retail relationships.

Macro & geopolitical exposure

Because Colgate-Palmolive is a global household and personal-products company, its natural macro exposures are input commodities, currency and consumer purchasing power rather than cyclical demand swings. Key sensitivities include:

• Raw materials: resins, palm oil derivatives, petrochemicals, paperboard and grains used in pet food can all affect cost of goods sold.
• Currency: with over 84% of employees outside the U.S. and sales in over 200 countries and territories, FX translation is a constant headwind or tailwind.
• Trade policy: tariffs or cross-border restrictions on ingredients, packaging or finished goods can ripple through an agile but globally dispersed supply chain.
• Regulation: personal care ingredient rules, oral care claims standards and pet food labeling and safety requirements are all relevant to the categories Colgate-Palmolive competes in.
• Consumer behavior: persistent inflation can push shoppers toward private-label alternatives in home care and personal care, while premium pet nutrition may prove more resilient.

Recent developments

Recent headlines reflect two investor preoccupations: dividend sustainability and the North America growth trajectory.

• September 18, 2026 — Seeking Alpha published “The Dividend Kings Ranked By Quality Scores (September 2026),” placing Colgate-Palmolive within the dividend-king conversation.
• September 17, 2026 — Business Wire reported that Colgate-Palmolive declared its regular quarterly dividend, reaffirming the income angle that dominates coverage of the stock.
• September 17, 2026 — 247wallst.com asked, “One of These Dividend Kings Pays Out More Than It Earns. Which Dividend Is Safer?”—a headline that highlights market scrutiny of payout coverage among ultra-long dividend-growth names.
• September 16, 2026 — Zacks.com asked, “Can Colgate Revive North America Growth in the Second Half?” This points to ongoing analyst focus on geographic sales momentum, particularly in the company’s large but challenged North American market.

Earnings behavior & post-earnings drift

Colgate-Palmolive has an exceptionally consistent earnings record over the last eight reported quarters: it beat the consensus estimate in all 8 quarters (100% beat rate), with an average earnings surprise of 3.3%. The average 5-day price move after earnings across those quarters is +2.32%, classified as an “up” drift.

The four most recent reports show a clear pattern of beats followed by mixed immediate reactions:

• July 31, 2026: EPS $0.99 vs. estimate $0.947, a 4.5% surprise. The stock fell 1.56% the next day but rose 2.16% over the following five sessions.
• May 1, 2026: EPS $0.97 vs. estimate $0.943, a 2.9% surprise. The stock dropped 2.17% the next day and gained only 0.33% over the next five sessions.
• January 30, 2026: EPS $0.95 vs. estimate $0.912, a 4.2% surprise. The stock rose 1.77% the next day and 4.56% over the following five sessions.
• October 31, 2025: EPS $0.91 vs. estimate $0.889, a 2.4% surprise. The stock fell 2.69% the next day but rebounded 2.22% over the next five sessions.

The takeaway from this history is not a directional call, but a behavioral tendency: even when results exceed the official consensus, Colgate-Palmolive has often sold off the next day, while a positive five-day drift has been the more common outcome. The next scheduled report is October 30, 2026, before the open, with a current consensus EPS estimate of $0.92.

For traders and investors wanting to go further than the headline numbers, the full institutional verdict on CL—covering analyst rating distributions, revision trends and forward expectations—offers the deeper context needed to interpret whether the current 34.1x P/E, the 100% beat rate and the “up” post-earnings drift are aligning with broader Wall Street positioning.